An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia

Akihiro Shiina, Nobuhisa Kanahara, Tsuyoshi Sasaki, Yasunori Oda, Tasuku Hashimoto, Tadashi Hasegawa, Taisuke Yoshida, Masaomi Iyo, Kenji Hashimoto, Akihiro Shiina, Nobuhisa Kanahara, Tsuyoshi Sasaki, Yasunori Oda, Tasuku Hashimoto, Tadashi Hasegawa, Taisuke Yoshida, Masaomi Iyo, Kenji Hashimoto

Abstract

Objective: Schizophrenia is a mental disorder characterized by severe cognitive impairment. Accumulating evidence suggests a role for oxidative stress in the pathophysiology of schizophrenia. Sulforaphane (SFN) extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. In this study, we attempted to evaluate the effect of SFN on cognitive impairment in medicated patients with schizophrenia.

Methods: We recruited a total of 10 outpatients with schizophrenia, all of whom gave informed consent. Participants took 3 tablets of SFN, consisting of 30 mg of SFN-glucosinolate per day, for 8 weeks. Clinical symptoms using the Positive and Negative Syndrome Scale (PANSS) and cognitive function using the Japanese version of CogState battery were evaluated at the beginning of the study and at week 8.

Results: A total of 7 patients completed the trial. The mean score in the Accuracy component of the One Card Learning Task increased significantly after the trial. However, we detected no other significant changes in participants.

Conclusions: This result suggests that SFN has the potential to improve cognitive function in patients with schizophrenia.

Keywords: Clinical trial; CogState; Executive function; Schizophrenia; Sulforafan.

References

    1. Elvevåg B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14:1–21. doi: 10.1615/CritRevNeurobiol.v14.i1.10.
    1. Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci. 2012;16:27–34. doi: 10.1016/j.tics.2011.11.015.
    1. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 2008;161:235–247. doi: 10.1016/j.psychres.2007.07.012.
    1. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57:209–219. doi: 10.1016/S0920-9964(01)00312-7.
    1. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry. 2006;67( Suppl 9):3–8. doi: 10.4088/JCP.1006e12.
    1. Ibrahim HM, Tamminga CA. Treating impaired cognition in schizophrenia. Curr Pharm Biotechnol. 2012;13:1587–1594. doi: 10.2174/138920112800784772.
    1. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176–184. doi: 10.1176/appi.ajp.158.2.176.
    1. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233–255. doi: 10.1093/oxfordjournals.schbul.a033376.
    1. Sumiyoshi T, Higuchi Y, Uehara T. Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia. Front Behav Neurosci. 2013;7:140. doi: 10.3389/fnbeh.2013.00140.
    1. Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, et al. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology. 2013;38:968–975. doi: 10.1038/npp.2012.259.
    1. Shiina A, Shirayama Y, Niitsu T, Hashimoto T, Yoshida T, Hasegawa T, et al. A randomised, double-blind, placebo- controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry. 2010;9:27. doi: 10.1186/1744-859X-9-27.
    1. Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, et al. A randomized, double-blind, placebo- controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol. 2012;32:593–601. doi: 10.1097/JCP.0b013e3182664cfc.
    1. Niitsu T, Iyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr Pharm Des. 2012;18:875–883. doi: 10.2174/138161212799436476.
    1. Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M, et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2014;24:223–231. doi: 10.1016/j.euroneuro.2013.11.012.
    1. Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013;70:1267–1275. doi: 10.1001/jamapsychiatry.2013.2159.
    1. Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, et al. Clinical trials of potential cognitive- enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull. 2013;39:417–435. doi: 10.1093/schbul/sbr153.
    1. Do KQ, Conus P, Cuenod M. Redox dysregulation and oxidative stress in schizophrenia: nutrigenetics as a challenge in psychiatric disease prevention. World Rev Nutr Diet. 2010;101:131–153. doi: 10.1159/000314518.
    1. Saruwatari J, Yasui-Furukori N, Kamihashi R, Yoshimori Y, Oniki K, Tsuchimine S, et al. Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia. Neuropsychiatr Dis Treat. 2013;9:1683–1698. doi: 10.2147/NDT.S52585.
    1. Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal. 2011;15:2011–2035. doi: 10.1089/ars.2010.3603.
    1. Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011;35:878–893. doi: 10.1016/j.neubiorev.2010.10.008.
    1. Zhang XY, Chen da C, Xiu MH, Tang W, Zhang F, Liu L, et al. Plasma total antioxidant status and cognitive impairments in schizophrenia. Schizophr Res. 2012;139:66–72. doi: 10.1016/j.schres.2012.04.009.
    1. Wu JQ, Chen da C, Tan YL, Tan SP, Wang ZR, Xiu MH, et al. Cognition impairment in schizophrenia patients with tardive dyskinesia: association with plasma superoxide dismutase activity. Schizophr Res. 2014;152:210–216. doi: 10.1016/j.schres.2013.11.010.
    1. Zhang XY, Chen da C, Xiu MH, Tan YL, Yang FD, Zhang LY, et al. Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: a case-control study. J Psychiatr Res. 2013;47:1049–1053. doi: 10.1016/j.jpsychires.2013.03.014.
    1. Gubert C, Stertz L, Pfaffenseller B, Panizzutti BS, Rezin GT, Massuda R, et al. Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. J Psychiatr Res. 2013;47:1396–1402. doi: 10.1016/j.jpsychires.2013.06.018.
    1. Reddy R, Reddy R. Antioxidant therapeutics for schizophrenia. Antioxid Redox Signal. 2011;15:2047–2055. doi: 10.1089/ars.2010.3571.
    1. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361–368. doi: 10.1016/j.biopsych.2008.03.004.
    1. Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs. 2001;15:287–310. doi: 10.2165/00023210-200115040-00004.
    1. Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2001;62:878–883. doi: 10.4088/JCP.v62n1107.
    1. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry. 2002;159:1596–1598. doi: 10.1176/appi.ajp.159.9.1596.
    1. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:463–493. doi: 10.1016/S0278-5846(00)00181-0.
    1. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001;49:243–251. doi: 10.1016/S0920-9964(00)00083-9.
    1. Peet M, Horrobin DF E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyleicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res. 2002;36:7–18. doi: 10.1016/S0022-3956(01)00048-6.
    1. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001;158:2071–2074. doi: 10.1176/appi.ajp.158.12.2071.
    1. Chengappa KN, Turkin SR, DeSanti S, Bowie CR, Brar JS, Schlicht PJ, et al. A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia. Schizophr Res. 2012;142:145–152. doi: 10.1016/j.schres.2012.10.001.
    1. Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci. 2007;64:1105–1127. doi: 10.1007/s00018-007-6484-5.
    1. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A. 2002;99:7610–7615. doi: 10.1073/pnas.112203099.
    1. Chen H, Wu J, Zhang J, Fujita Y, Ishima T, Iyo M, et al. Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine. Psychopharmacology (Berl) 2012;222:37–45. doi: 10.1007/s00213-011-2619-3.
    1. Shirai Y, Fujita Y, Hashimoto K. Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine administration. Clin Psychopharmacol Neurosci. 2012;10:94–98. doi: 10.9758/cpn.2012.10.2.94.
    1. Hashimoto K. Brain-derived neurotrophic factor as a bio-marker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci. 2010;64:341–357. doi: 10.1111/j.1440-1819.2010.02113.x.
    1. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol. 2013;100:15–29. doi: 10.1016/j.pneurobio.2012.09.001.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Arlington, VA, USA: American Psychiatric Press; 2000.
    1. Yoshida T, Suga M, Arima K, Muranaka Y, Tanaka T, Eguchi S, et al. Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia. PLoS One. 2011;6:e20469. doi: 10.1371/journal.pone.0020469.
    1. Lim YY, Jaeger J, Harrington K, Ashwood T, Ellis KA, Stöffler A, et al. Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer’s disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS) Arch Clin Neuropsychol. 2013;28:320–330. doi: 10.1093/arclin/act021.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276. doi: 10.1093/schbul/13.2.261.
    1. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007;4:28–37.
    1. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008;165:214–220. doi: 10.1176/appi.ajp.2007.07010043.
    1. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–213. doi: 10.1176/appi.ajp.2007.07010042.
    1. Pietrzak RH, Snyder PJ, Jackson CE, Olver J, Norman T, Piskulic D, et al. Stability of cognitive impairment in chronic schizophrenia over brief and intermediate re-test intervals. Hum Psychopharmacol. 2009;24:113–121. doi: 10.1002/hup.998.
    1. Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol. 2009;24:165–178. doi: 10.1093/arclin/acp010.
    1. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One. 2012;7:e42676. doi: 10.1371/journal.pone.0042676.
    1. Wild K, Howieson D, Webbe F, Seelye A, Kaye J. Status of computerized cognitive testing in aging: a systematic review. Alzheimers Dement. 2008;4:428–437. doi: 10.1016/j.jalz.2008.07.003.
    1. Fredrickson J, Maruff P, Woodward M, Moore L, Fredrickson A, Sach J, et al. Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies. Neuroepidemiology. 2010;34:65–75. doi: 10.1159/000264823.
    1. Ichimura S, Ohira T, Kobayashi M, Kano T, Akiyama T, Orii M, et al. Assessment of cognitive function before and after surgery for posterior cranial fossa lesions using computerized and conventional tests. Neurol Med Chir (Tokyo) 2010;50:441–448. doi: 10.2176/nmc.50.441.
    1. Lim YY, Ellis KA, Harrington K, Ames D, Martins RN, Masters CL, et al. Use of the CogState Brief Battery in the assessment of Alzheimer’s disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Clin Exp Neuropsychol. 2012;34:345–358. doi: 10.1080/13803395.2011.643227.
    1. Mas S, Gassó P, Trias G, Bernardo M, Lafuente A. Sulforaphane protects SK-N-SH cells against antipsychotic- induced oxidative stress. Fundam Clin Pharmacol. 2012;26:712–721. doi: 10.1111/j.1472-8206.2011.00988.x.
    1. Falleti MG, Maruff P, Collie A, Darby DG. Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J Clin Exp Neuropsychol. 2006;28:1095–1112. doi: 10.1080/13803390500205718.
    1. Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 2009;31:848–859. doi: 10.1080/13803390802592458.
    1. Darby DG, Pietrzak RH, Fredrickson J, Woodward M, Moore L, Fredrickson A, et al. Intraindividual cognitive decline using a brief computerized cognitive screening test. Alzheimers Dement. 2012;8:95–104. doi: 10.1016/j.jalz.2010.12.009.
    1. Hammers D, Spurgeon E, Ryan K, Persad C, Heidebrink J, Barbas N, et al. Reliability of repeated cognitive assessment of dementia using a brief computerized battery. Am J Alzheimers Dis Other Demen. 2011;26:326–333. doi: 10.1177/1533317511411907.
    1. Cole WR, Arrieux JP, Schwab K, Ivins BJ, Qashu FM, Lewis SC. Test-retest reliability of four computerized neurocognitive assessment tools in an active duty military population. Arch Clin Neuropsychol. 2013;28:732–742. doi: 10.1093/arclin/act040.
    1. Murthy NV, Mahncke H, Wexler BE, Maruff P, Inamdar A, Zucchetto M, et al. Computerized cognitive remediation training for schizophrenia: an open label, multi-site, multinational methodology study. Schizophr Res. 2012;139:87–91. doi: 10.1016/j.schres.2012.01.042.
    1. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry. 2011;16:960–972. doi: 10.1038/mp.2010.88.
    1. Pandya CD, Kutiyanawalla A, Pillai A. BDNF-TrkB signaling and neuroprotection in schizophrenia. Asian J Psychiatr. 2013;6:22–28. doi: 10.1016/j.ajp.2012.08.010.
    1. Carlino D, De Vanna M, Tongiorgi E. Is altered BDNF biosynthesis a general feature in patients with cognitive dysfunctions? Neuroscientist. 2013;19:345–353. doi: 10.1177/1073858412469444.
    1. Nurjono M, Lee J, Chong SA. A review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia. Clin Psychopharmacol Neurosci. 2012;10:61–70. doi: 10.9758/cpn.2012.10.2.61.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren